Acute electrophysiologic effects of inhaled salbutamol in humans

被引:49
作者
Kallergis, EM
Manios, EG
Kanoupakis, EM
Schiza, SE
Mavrakis, HE
Klapsinos, NK
Vardas, PE [1 ]
机构
[1] Heraklion Univ Hosp, Dept Cardiol, Iraklion 71000, Crete, Greece
[2] Heraklion Univ Hosp, Dept Pneumol, Iraklion 71000, Crete, Greece
关键词
beta(2)-agonist; electrophysiologic effects; refractory period; salbutamol;
D O I
10.1378/chest.127.6.2057
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: Although inhaled beta(2)-agonists are in widespread use, several reports question their potential arrhythmogenic effects. The purpose of this study was to evaluate the cardiac electrophysiologic effects of a single, regular dose of an inhaled beta(2)-agonist in humans. Design: Prospective study. Setting: Tertiary referral center. Patients: Six patients with bronchial asthma and 12 patients with mild COPD. Interventions: All patients underwent an electrophysiologic study before and after the administration of salbutamol solution (5 mg in a single dose). Measurements and results: Sinus cycle length, sinus node recovery time (SNRT), interval from the earliest reproducible rapid deflection of the atrial electrogram in the His bundle recording to the onset of the His deflection (AH), interval from the His deflection to the onset of ventricular depolarization (HV), Wenckebach cycle length (WCL), atrial effective refractory period (AERP), and ventricular effective refractory period (VERP) were evaluated just before and 30 min after the scheduled intervention. Salbutamol, a selective beta(2)-agonist, administered by nebulizer had significant electrophysiologic effects on the atrium, nodes, and ventricle. The AH length decreased from 86.1 +/- 19.5 ms at baseline to 78.8 +/- 18.4 ms (p < 0.001), and the WCL decreased from 354.4 +/- 44.2 to 336.6 +/- 41.7 ms (p = 0.001). Salbutamol significantly decreased the AERP and VERP too while leaving the HV unchanged. Additionally, inhaled salbutamol increased heart rate (from 75.5 +/- 12.8 beats/min at baseline to 93.1 +/- 16 beats/min, p < 0.001) and shortened the SNRT (from 1,073.5 +/- 178.7 to 925.2 +/- 204.9 ms, p = 0.001). Conclusion: Inhaled salbutamol results in significant changes of cardiac electrophysiologic properties. Salbutamol enhances atrioventricular (AV) nodal conduction and decreases AV nodal, atrial, and ventricular refractoriness in addition to its positive chronotropic effects. These alterations could contribute to the generation of spontaneous arrhythmias.
引用
收藏
页码:2057 / 2063
页数:7
相关论文
共 33 条
[1]   INCIDENCE OF CARDIAC-ARRHYTHMIAS IN PATIENTS TAKING SLOW RELEASE SALBUTAMOL AND SLOW RELEASE TERBUTALINE FOR ASTHMA [J].
ALHILLAWI, AH ;
HAYWARD, R ;
JOHNSON, NM .
BRITISH MEDICAL JOURNAL, 1984, 288 (6414) :367-367
[2]   EXTRA-PULMONARY EFFECTS OF TERBUTALINE DURING PROLONGED ADMINISTRATION [J].
BENGTSSON, B ;
FAGERSTROM, PO .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (06) :726-732
[3]   beta(2)-Adrenergic receptor antagonists protect against ventricular fibrillation - In vivo and in vitro evidence for enhanced sensitivity to beta(2)-adrenergic stimulation in animals susceptible to sudden death [J].
Billman, GE ;
Castillo, LC ;
Hensley, J ;
Hohl, CM ;
Altschuld, RA .
CIRCULATION, 1997, 96 (06) :1914-1922
[4]   BETA-1-ADRENERGIC-RECEPTOR AND BETA-2-ADRENERGIC-RECEPTOR SUBPOPULATIONS IN NONFAILING AND FAILING HUMAN VENTRICULAR MYOCARDIUM - COUPLING OF BOTH RECEPTOR SUBTYPES TO MUSCLE-CONTRACTION AND SELECTIVE BETA-1-RECEPTOR DOWN-REGULATION IN HEART-FAILURE- [J].
BRISTOW, MR ;
GINSBURG, R ;
UMANS, V ;
FOWLER, M ;
MINOBE, W ;
RASMUSSEN, R ;
ZERA, P ;
MENLOVE, R ;
SHAH, P ;
JAMIESON, S ;
STINSON, EB .
CIRCULATION RESEARCH, 1986, 59 (03) :297-309
[5]  
BRISTOW MR, 1990, CIRCULATION, V82, P112
[6]  
BRISTOW MR, 1993, J AM COLL CARDIOL, V22, P61
[7]  
Brodde OE, 1999, PHARMACOL REV, V51, P651
[8]  
BRODDE OE, 1991, PHARMACOL REV, V43, P203
[9]   CHARACTERIZATION AND AUTORADIOGRAPHIC LOCALIZATION OF BETA-ADRENOCEPTOR SUBTYPES IN HUMAN CARDIAC TISSUES [J].
BUXTON, BF ;
JONES, CR ;
MOLENAAR, P ;
SUMMERS, RJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1987, 92 (02) :299-310
[10]   Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [J].
Celli, BR ;
MacNee, W ;
Agusti, A ;
Anzueto, A ;
Berg, B ;
Buist, AS ;
Calverley, PMA ;
Chavannes, N ;
Dillard, T ;
Fahy, B ;
Fein, A ;
Heffner, J ;
Lareau, S ;
Meek, P ;
Martinez, F ;
McNicholas, W ;
Muris, J ;
Austegard, E ;
Pauwels, R ;
Rennard, S ;
Rossi, A ;
Siafakas, N ;
Tiep, B ;
Vestbo, J ;
Wouters, E ;
ZuWallack, R .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (06) :932-946